Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Agios Pharmaceuticals

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities5.30%
Size of stake in company6.40%
Market capitalizationUSD 2.3 bn

Sector

Rare Diseases

Main candidate

Pyrukynd Mitapivat  (Pyruvate Kinase deficiency)

Main indications

Hemolytic anemias

About the company

Agios Pharmaceuticals is a biotechnology company founded in 2008 and headquartered in Cambridge, Massachusetts (US), focused on developing new drugs for genetically defined diseases. Today, the company´s focus is on hemolytic anemias. In 2022 Pyrukynd (Mitapivat) a first-in-class PK activator was approved in the US and EU for the treatment of adults patients with pyruvate kinase (PK) deficiency. The company is currently exploiting α- and β-thalassemia and Sickle Cell Disease as label extension opportunities for the same asset.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.